Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Medroxyprogesterone
Sayana Press · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sayana Press, Upper Arm injection | EXPERIMENTAL | Sayana Press, administered subcutaneously into upper arm |
| Sayana Press, anterior thigh | ACTIVE_COMPARATOR | Sayana Press, administered subcutaneously into anterior thigh |
| Sayana Press, abdomen | ACTIVE_COMPARATOR | Sayana Press, administered subcutaneously into abdomen |
| Name | Type | Description |
|---|---|---|
| Sayana Press | COMBINATION_PRODUCT | Sayana Press is a drug-device combination and is considered a medical product in the EU. |
Inclusion Criteria: * Pre-menopausal female participants, 18 to 45 years of age, inclusive, at the time of signing the ICD who are at low risk of pregnancy * Participants who have a regular menstrual cycle (between 21 and 42 days in length). * No previous injection of depot MPA for 1 year prior to ...
Sayana Press is an injectable small molecule developed by Pfizer, Inc. (ticker: PFE). It has been studied in a Phase 1 clinical trial in healthy female volunteers. The specific therapeutic indication for Sayana Press is undisclosed.
Sayana Press is made by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the developer responsible for the clinical testing of Sayana Press.
Sayana Press is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently listed as active in further trials. It is an investigational product and has not been approved by the FDA.
Sayana Press has been evaluated in one completed Phase 1 trial, NCT04893798. The study compared subcutaneous injection of Sayana Press in the upper arm versus the anterior thigh and abdomen. It enrolled 67 healthy female volunteers aged 18 years and older in Belgium.
In the completed Phase 1 trial NCT04893798, Sayana Press was given as a subcutaneous injection. The study compared administration in the upper arm versus the anterior thigh and abdomen. The trial was active-controlled, randomized, and enrolled 67 healthy female volunteers in Belgium.